dfhgkdf
Monday, April 11, 2011
Friday, April 8, 2011
Tuesday, March 29, 2011
Monday, March 28, 2011
Friday, March 25, 2011
Wednesday, March 23, 2011
Tuesday, March 22, 2011
Monday, March 21, 2011
Saturday, March 19, 2011
Test 12 No image
no image
sdsfjsdlj
sdgsl;dg
sg
dfg
df
g
fd
hbg
h
gfj
gf
j
h
jh
gj
hglfkghl';gfj
ghnjgfjgf
sdsfjsdlj
sdgsl;dg
sg
dfg
df
g
fd
hbg
h
gfj
gf
j
h
jh
gj
hglfkghl';gfj
ghnjgfjgf
Friday, March 18, 2011
Wednesday, March 16, 2011
Tuesday, March 15, 2011
Monday, March 14, 2011
Test 33
Deferiprone
From Wikipedia, the free encyclopedia
Jump to: navigation, search
Systematic (IUPAC) name | |
---|---|
3-hydroxy-1,2-dimethylpyridin-4(1H)-one | |
Identifiers | |
CAS number | 30652-11-0 |
ATC code | V03AC02 |
PubChem | CID 2972 |
ChemSpider | 2866 |
KEGG | D07416 |
ChEMBL | CHEMBL70927 |
Chemical data | |
Formula | C7H9NO2 |
Mol. mass | 139.152 g/mol |
SMILES | eMolecules & PubChem |
Pharmacokinetic data | |
Metabolism | Glucuronidation |
Half-life | 2 to 3 hours |
Excretion | Renal (75 to 90% in 24 hours) |
Therapeutic considerations | |
Licence data | EMA:Link |
Pregnancy cat. | ? |
Legal status | ? |
Routes | Oral |
|
It is currently licensed for use in Europe and Asia, but not in Canada and the United States.[1][2]
Deferiprone is in clinical trials in the United States to treat Contrast-Induced Acute Kidney Injury and to slow progression of Chronic Kidney Disease; the trials are being conducted by the biotech company, Cormedix.[3]